(Competitive Insight/Unsplash) While GLP-1 drugs such as Wegovy and Ozempic are now being broadly championed and widely used, ...

The weight-loss drugs market is set to grow to around Rs 5,000 crore in India by 2030, up from Rs 1,000 crore at present, ...

Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...

A bull Put options strategy is favored over direct equity due to AMPH’s lack of moat or high growth. My last article about Amphastar Pharmaceuticals, Inc. ( AMPH) was in July, last year. This is a ...

Researchers found that the odds of developing an eye condition that leads to vision loss were about 5 times higher among ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...

Ozempic is intended to help people with diabetes manage blood sugar. A dietitian breaks down exactly what Ozempic is, and if ...

Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the ...

Lilly is warning the public that tirzepatide mixed with B12 is creating an impurity with “unknown effects” in humans.

In the warning letter, the FDA alleged that Novo inadequately responded to observations made after an inspection carried out across January and February of 2025.

The blockbuster GLP-1 drugs that reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce their tragic outcomes, a large new study found.

Prescription weight loss drugs have been lauded as the miracle drug for treating diabetes and obesity, but new research suggests that these drugs, known as glucagon-like peptide-1 (GLP-1) ...